• Neonatal BCG vaccine reduces atopic dermatitis prevalence in children

    Neonatal Bacillus Calmette-Guérin (BCG) vaccine reduced the prevalence of atopic dermatitis (AD) at 13 months in infants with atopic predisposition, said Danish researchers at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016 in Vienna, Austria.

  • Which weight-loss drugs are effective for treating obesity?
    Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.
  • Compression stockings do not prevent post thrombotic syndrome
    Using elastic compression stockings does not significantly reduce the development of post thrombotic syndrome in patients with deep venous thrombosis, according to a study.
  • Tenofovir prevents hepatitis B transmission in pregnancy
    The use of tenofovir disoproxil fumarate (TDF) during pregnancy resulted in lower rate of mother-to-child transmission of hepatitis B virus (HBV) compared with those who received usual care without antiviral therapy, a recent study finds.
  • Duration, dose of inhaled corticosteroids may affect body composition
    Longer duration and higher dose of inhaled corticosteroids (ICS) were associated with higher body fat composition and body mass index (BMI) in asthma patients, according to two studies presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2016 held in Vienna, Austria.
  • Once daily dabigatran 150mg safe and effective for adults with renal  impairment undergoing THR/TKR
    Once daily dabigatran 150mg is safe and effective for adults with renal impairment undergoing total hip or knee replacement (THR/TKR), as stated in a single-arm, open-label, phase IV study in Caucasian patients.
  • Original New Drug Application Approvals by US FDA (1 - 15 June 2016)
    New drug applications approved by US FDA as of 1 - 15 June 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
  • Budesonide prompts remission of ulcerative colitis
    Budesonide effectively prompts remission in a group of patients with mild-moderate ulcerative colitis, as shown in a review.
  • Sulodexide and diosmin-hesperidin, beneficial in the treatment of venous ulcer
    Sulodexide and diosmin-hesperidin hastened healing of ulcer, and improved pain and lipodermatosclerosis among patients with venous ulcer, as presented in an open-label, observational, non-parallel trial.
  • Omalizumab facilitates asthma control in obese patients
    Omalizumab shows therapeutic potential in severe asthma, yielding significant improvements in forced expiratory volume in 1 second (FEV1) and reductions in inhaled corticosteroid dose in obese compared to non-obese patients, according to a study presented at the European Academy of Allergology and Clinical Immunology (EAACI) Congress 2016 held recently in Vienna, Austria.